Analysts Issue Forecasts for Metagenomi FY2025 Earnings

Metagenomi, Inc. (NASDAQ:MGX) – Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Metagenomi in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.47) per share for the year. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. Chardan Capital also issued estimates for Metagenomi’s FY2026 earnings at ($0.76) EPS.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The business had revenue of $9.61 million for the quarter, compared to analyst estimates of $13.18 million. Metagenomi had a negative return on equity of 43.23% and a negative net margin of 134.27%. During the same quarter in the previous year, the business posted ($20.05) earnings per share.

Several other research firms have also weighed in on MGX. Wells Fargo & Company lowered their price objective on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday, March 18th. HC Wainwright lifted their price target on shares of Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.40.

Metagenomi Price Performance

NASDAQ MGX opened at $1.59 on Thursday. Metagenomi has a one year low of $1.56 and a one year high of $11.80. The business has a 50 day simple moving average of $2.30 and a 200 day simple moving average of $2.45. The stock has a market capitalization of $59.44 million and a P/E ratio of -0.61.

Institutional Trading of Metagenomi

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its stake in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after purchasing an additional 7,256 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Metagenomi in the third quarter valued at approximately $82,000. Geode Capital Management LLC boosted its position in shares of Metagenomi by 105.8% during the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock valued at $734,000 after buying an additional 173,796 shares during the last quarter. Peapod Lane Capital LLC bought a new stake in Metagenomi during the fourth quarter worth $1,268,000. Finally, Rhumbline Advisers raised its position in Metagenomi by 123.3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock valued at $43,000 after buying an additional 6,626 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.